Matthias Therapeutics, LLC
Summary
Matthias Therapeutics, LLC raised $65.0M in an initial Form D filing on 2026-06-01, with Flagship Pioneering and ARCH Venture Partners as related persons. The large raise and top-tier VC involvement signal strong investor confidence in the company's technology venture. The filing is a first notice, with no prior amendments.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Matthias Therapeutics, LLC raised $65.0M in an initial Form D filing on 2026-06-01, with Flagship Pioneering and ARCH Venture Partners as related persons. The large raise and top-tier VC involvement signal strong investor confidence in the company's technology venture. The filing is a first notice, with no prior amendments.
Investor Edge
Watch for a D/A amendment within 90 days, which would indicate the company is expanding the round or changing terms. Sophisticated investors should track subsequent SEC filings for any hint of a future IPO or SPAC merger, given the involvement of two top VC firms.
Sector capital positioning
This $65M raise in Technology Venture underscores continued heavy capital flow into deep-tech, high-capital-expenditure startups, likely targeting therapeutics or platform biology. The participation of Flagship and ARCH reinforces their focus on transformative life science bets.
Convergence Signals
No obvious public market convergence signals from this filing alone – no patents, contracts, or legislation mentioned. Monitor for future D/A amendments or public announcements revealing specific technology or partnerships.
Key Takeaways
- $65.0M raised in a single private placement, a significant sum for an initial Form D.
- Flagship Pioneering and ARCH Venture Partners listed as related persons, indicating top-tier VC backing.
- No public ticker or prior amendments; future D/A filings will be key to track capital growth.
Risk Indicators & Flags
No red flags from this initial filing. However, the large amount for a private Tech Venture LLC could imply high burn rate or aggressive valuation. Regulatory concerns: none apparent.
Verification & References
Filing is an initial Form D by Matthias Therapeutics, LLC (SEC CIK 0002104165) filed on 2026-06-02 with first sale 2026-06-01. Accession number 000210416526000003. Verify at SEC EDGAR.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Dare Bioscience, Inc.
Uniform Bio Inc.
DEF 14A - Outlook Therapeutics, Inc.
Anika Therapeutics, Inc.
Strategy Inc
Outlook Therapeutics, Inc.
Pacira BioSciences, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Securing the Nation Against Advanced Cryptographic Attacks
This executive order mandates a nationwide transition of federal information systems and critical infrastructure to post-quantum cryptography (PQC) by specific deadlines (2030 for key establishment, 2031 for digital signatures), directs NIST to lead technical guidance and a pilot project, requires agencies to appoint PQC migration leads, and orders the Federal Acquisition Regulatory Council to propose rules requiring contractors to comply with NIST PQC standards by 2030.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →